Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DRNA Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Dicerna Pharmaceuticals Stock (NASDAQ:DRNA) 30 days 90 days 365 days Advanced Chart Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get DRNA alerts:Sign Up Key Stats Today's Range$38.22▼$38.2250-Day Range$37.81▼$38.2552-Week Range$19.06▼$40.14VolumeN/AAverage Volume1.34 million shsMarket Capitalization$2.99 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewDicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.Read More… Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Dicerna Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks23rd Percentile Overall ScoreDRNA MarketRank™: Dicerna Pharmaceuticals scored higher than 23% of companies evaluated by MarketBeat, and ranked 892nd out of 998 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Dicerna Pharmaceuticals.Read more about Dicerna Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dicerna Pharmaceuticals are expected to grow in the coming year, from ($1.59) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dicerna Pharmaceuticals is -23.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dicerna Pharmaceuticals is -23.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDicerna Pharmaceuticals has a P/B Ratio of 20.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DRNA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDicerna Pharmaceuticals does not currently pay a dividend.Dividend GrowthDicerna Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.77 Short InterestThere is no current short interest data available for DRNA. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Dicerna Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dicerna Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.20% of the stock of Dicerna Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.91% of the stock of Dicerna Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dicerna Pharmaceuticals' insider trading history. Receive DRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DRNA Stock News HeadlinesArrowhead Pharmaceuticals (NASDAQ: ARWR)May 25, 2023 | fool.com'Mad Money' Lightning Round: I'm Staying Away From Five BelowFebruary 16, 2023 | thestreet.comAlgo Trading Is Here 🔥One trade alert each day backed by powerful technology, yours free. For $0 you can get access to one daily stock picked directly from StocksToTrade’s algo-powered system.October 26, 2024 | Timothy Sykes (Ad)BiondVax Pharmaceuticals Stock (NASDAQ:BVXV), Quotes and News SummaryFebruary 7, 2023 | benzinga.comMyc Proto-Oncogene Protein Market 2023 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028January 26, 2023 | marketwatch.comWe Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business GrowthJanuary 19, 2023 | finance.yahoo.comDRNA Jan 2022 22.500 callJanuary 14, 2022 | ca.finance.yahoo.comDRNA Jul 2022 40.000 call(CONTRJanuary 14, 2022 | ca.finance.yahoo.comSee More Headlines DRNA Stock Analysis - Frequently Asked Questions How were Dicerna Pharmaceuticals' earnings last quarter? Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) released its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.19. The biopharmaceutical company had revenue of $62.95 million for the quarter, compared to analyst estimates of $58.83 million. Dicerna Pharmaceuticals had a negative net margin of 64.53% and a negative trailing twelve-month return on equity of 103.08%. What other stocks do shareholders of Dicerna Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Marvell Technology (MRVL), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and PayPal (PYPL). Company Calendar Last Earnings11/09/2021Today10/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:DRNA CUSIPN/A CIK1399529 Webwww.dicerna.com Phone(617) 621-8097Fax617-612-6298Employees302Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,750,000.00 Net Margins-64.53% Pretax Margin-63.82% Return on Equity-103.08% Return on Assets-16.58% Debt Debt-to-Equity RatioN/A Current Ratio2.46 Quick Ratio2.46 Sales & Book Value Annual Sales$164.31 million Price / Sales18.17 Cash FlowN/A Price / Cash FlowN/A Book Value$1.84 per share Price / Book20.77Miscellaneous Outstanding Shares78,129,000Free Float70,160,000Market Cap$2.99 billion OptionableOptionable Beta0.80 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:DRNA) was last updated on 10/26/2024 by MarketBeat.com Staff From Our PartnersAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“Hear That Whoosh Sound? It’s the Great Power Suck of 2025”We’re coming to the end of the line for the traditional energy grid. Look what’s happening in California.Traders Agency | SponsoredInvest in the company that won over the DragonsThe pioneer in smart-doorbell technology, RING, pitched their business on the hit show Shark Tank at a valuati...RYSE | SponsoredPutin proposes new currencyRussian leader Vladimir Putin just unveiled the first physical mockup of a proposed new currency. Many spec...Stansberry Research | SponsoredONE crypto stock +526% in under 60 daysCryptos are screaming higher right now. Yet, this ONE started a shooting up a little under 60 days ago.The Bitcoin Capitalist | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dicerna Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dicerna Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.